Abstract 805P
Background
Complete tumor resection is the most relevant prognostic factor for overall survival in high grade serous ovarian cancer (HGSOC) patients. The current standard for classification of postoperative residual disease (RD) is surgeon´s subjective evaluation at the end of surgery. Thus, a reliable objective predictive marker is currently missing.
Methods
In this prospective single-center feasibility study, patients with HGSOC, who underwent surgery between July 2021 to December 2022, were included. Tumor tissue was assessed intraoperatively and blood samples were performed preoperatively, at day 2 and 10 postoperatively and subsequently at cycle 1, 3 and 6 of chemotherapy. Low-coverage whole genome sequencing (WGS) was used to identify structural variants (SV), single nucleotide variants (SNVs) and indels in tumor tissue in order to develop personalized digital PCR (dPCR) fingerprint assays.
Results
So far, 33 patients are included in the present analysis, with a median follow up time of 7 (IQR 2-10) months. In all tumor samples, dPCR assays were successfully developed and validated, with a median of 5 biomarkers (SVs and SNVs) per patient. For each patient, an individual SV profile could be established, which remained largely constant throughout multiple tumor localizations of each patient. 32/33 (97%) patients had circulating tumor DNA (ctDNA) detected at baseline at levels ranging from 0.0005 - 31% VAF. Three (10%) patients have been lost to follow without postoperative ctDNA samples. ctDNA was persistently detected in all patients with macroscopic tumor residuals. A significant decrease in ctDNA was observed in all patients with stage I-IIIB disease who had macroscopic complete resection (8 patients). In 8/22 (36%) patients with complete resection, ctDNA decreased below the detection limit. Clinical follow up is ongoing, and analysis of longitudinal samples will be presented at the congress.
Conclusions
In this feasibility study, tumor-informed ctDNA was preoperatively detectable in 97% participants. In patients with multiple tumor biopsies, the fingerprint could be used for monitoring of each location. A decrease in ctDNA detection correlated with complete tumor resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical University of Vienna.
Funding
SAGA Diagnostics.
Disclosure
C. Grimm: Financial Interests, Personal, Advisory Board: AstraZeneca, Celgene, Clovis, Eisai, GSK, MSD, PharmaMar, Roche, Sandoz; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Eisai, GSK, MSD, PharmaMar, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Meda Pharma, Roche Diagnostics. L. Saal: Financial Interests, Personal and Institutional, Ownership Interest: SAGA Diagnostics. C. Brueffer: Financial Interests, Personal and Institutional, Stocks/Shares: SAGA Diagnostics. N. Segui Gracia: Financial Interests, Personal and Institutional, Full or part-time Employment: SAGA Diagnostics. M. Alcaide: Financial Interests, Personal and Institutional, Stocks/Shares: SAGA Diagnostics. S. Polterauer: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, MSD. L. Oton: Financial Interests, Personal and Institutional, Stocks/Shares: SAGA Diagnostics. Y. Chen: Financial Interests, Personal and Institutional, Full or part-time Employment: SAGA Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
812P - Mental and socioeconomic burden in co-parents and children of patients with endometrial and cervical cancer: A Swedish population-based study
Presenter: Karin Sundström
Session: Poster session 11
814P - Clinical significance of isolated pulmonary recurrence in patients with endometrioid endometrial cancer who achieved complete remission after primary treatment
Presenter: Jigeun Yoo
Session: Poster session 11
815P - Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study
Presenter: Jerome Alexandre
Session: Poster session 11
816P - Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Presenter: Alain Zeimet
Session: Poster session 11
817P - A systematic review of recruitment of ethnic minorities to RCTs of systemic anti-cancer therapies in gynaecological cancers
Presenter: Luke Steventon
Session: Poster session 11